{"id":51075,"date":"2026-04-18T11:38:37","date_gmt":"2026-04-18T11:38:37","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/51075\/"},"modified":"2026-04-18T11:38:37","modified_gmt":"2026-04-18T11:38:37","slug":"how-roche-hopes-to-go-toe-to-toe-with-eli-lilly-novo-nordisk-in-obesity","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/51075\/","title":{"rendered":"How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity"},"content":{"rendered":"<p>Roche (RHHBY) hopes to go toe-to-toe with Eli Lilly (LLY) and Novo Nordisk (NVO) in the red-hot weight-loss space. The Swiss drug giant said Thursday it expects to seek approval for four new obesity drugs in 2028. &#8220;Every patient is on an individual weight-loss journey,&#8221; Teresa Graham, chief executive of Roche&#8217;s pharma division, said during the earnings conference call, according\u2026<\/p>\n","protected":false},"excerpt":{"rendered":"Roche (RHHBY) hopes to go toe-to-toe with Eli Lilly (LLY) and Novo Nordisk (NVO) in the red-hot weight-loss&hellip;\n","protected":false},"author":2,"featured_media":44721,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[23557,23558,230,134,29188,29189],"class_list":["post-51075","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-all-news-and-stock-ideas","tag-biotech-and-pharma-stock-news","tag-earnings","tag-roche","tag-snap-stories","tag-tech-earnings"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116425517071829758","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/51075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=51075"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/51075\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/44721"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=51075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=51075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=51075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}